What is the study drug?
The study drug, APL-101, is an investigational medicine designed to bind to and inhibit a protein called c-Met. The hope is that this will cause cell death in tumor cells overexpressing the c-Met protein or MET gene.
What is an investigational drug or medicine?
Investigational drugs are still being researched to see if they help patients with certain conditions. They are not approved by regulatory agencies, such as the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other regulatory authorities. They can only be used for research purposes.
All drugs approved by the FDA or other regulatory agencies were once investigational drugs.
Have other patients used the study drug?
Yes. The study drug has been studied in patients with advanced solid tumors in a Phase 1 study. This means the study drug has been studied to find out if it is safe.